Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer’s Disease

BR Cardoso; BR Roberts; CB Malpas; L Vivash; S Genc; MM Saling; P Desmond; C Steward; RJ Hicks; J Callahan; A Brodtmann; S Collins; S Macfarlane; NM Corcoran; CM Hovens; D Velakoulis; TJ O’Brien; DJ Hare; AI Bush

Journal article

Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer’s Disease

BR Cardoso, BR Roberts, CB Malpas, L Vivash, S Genc, MM Saling, P Desmond, C Steward, RJ Hicks, J Callahan, A Brodtmann, S Collins, S Macfarlane, NM Corcoran, CM Hovens, D Velakoulis, TJ O’Brien, DJ Hare, AI Bush

Neurotherapeutics | SPRINGER | Published : 2019

DOI: 10.1007/s13311-018-0662-z

Download PDF

Abstract

Insufficient supply of selenium to antioxidant enzymes in the brain may contribute to Alzheimer’s disease (AD) pathophysiology; therefore, oral supplementation may potentially slow neurodegeneration. We examined selenium and selenoproteins in serum and cerebrospinal fluid (CSF) from a dual-dose 24-week randomized controlled trial of sodium selenate in AD patients, to assess tolerability, and efficacy of selenate in modulating selenium concentration in the central nervous system (CNS). A pilot study of 40 AD cases was randomized to placebo, nutritional (0.32 mg sodium selenate, 3 times daily), or supranutritional (10 mg, 3 times daily) groups. We measured total selenium, selenoproteins, and i..

View full abstract

University of Melbourne Researchers

Charles Malpas Author

Michael Saling Author

Patricia Desmond Author

Chris Steward Author

Related Projects (3)

BIOMARKERS TO AID CLINICAL TRIALS FOR NEURODEGENERATIVE DISEASE

Alzheimer’s disease and Parkinson’s disease continue to affect more Australians every year, due to an ageing population and the lack of effe..

TACKLING KEY EPIDEMIOLOGICAL AND BASIC SCIENTIFIC RESEARCH ISSUES IN PRION DISEASES.

Proposed Practitioner Fellowship research will simultaneously include epidemiological and basic scientific projects, emphasising human prion..

TRACING IRON FROM NEURODEVELOPMENT TO NEURODEGENERATION IN PARKINSON'S DEISEASE

Excessive brain iron can cause neurodegeneration in Parkinson's disease (PD). This project will examine a link between early-life iron expos..

Grants

Awarded by NIHR Imperial Biomedical Research Centre

Funding Acknowledgements

Funded by Fellowships from the Brazilian Government Science Without Borders program (Ciencia sem Fronteiras; BRC), Deakin University (BRC), and the Australian National Health and Medical Research Council (GNT1138673, BRR; GNT1105784, SC; GNT1122981, DJH; GNT1103703, AIB); a Program Grant from the Australian National Health and Medical Research Council (GNT1132604, AIB); and by Velacor Therapeutics. Agilent Technologies provided material and research support (BRR, DJH).